Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir plus lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial

导出原文传递

翻译打印收藏纠错

作者： Lombardi, Francesca ^[1] ; Belmonti, Simone ^[2] ; Quiros-Roldan, Eugenia ^[3] ; Latini, Alessandra ^[4] ; Castagna, Antonella ^[5] ; D'Ettorre, Gabriella ^[6] ; Gagliardini, Roberta ^[7] ; Fabbiani, Massimiliano ; Cauda, Roberto ; De Luca, Andrea ; Di Giambenedetto, Simona

作者单位： San Gallicano Hosp, Unit Infect Dermatol, Rome, Italy ^[1] Univ Siena, Dept Med Biotechnol, Siena, Italy ^[2] Ist Sci San Raffaele, Dept Infect & Trop Dis, Milan, Italy ^[3] Univ Roma La Sapienza, Dept Infect Dis, Rome, Italy ^[4] Univ Brescia, Univ Div Infect & Trop Dis, Brescia, Italy ^[5] Univ Cattolica Sacro Cuore, Inst Clin Infect Dis, Rome, Italy ^[6] Univ Milano Bicocca, San Gerardo Hosp, Div Infect Dis, Dept Internal Med, Monza, Italy ^[7]

发布时间 2018-01-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

The Journal of Antimicrobial Chemotherapy

2017年72卷7期

2055-2059页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir plus lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial

The Journal of Antimicrobial Chemotherapy

相似文献

The Journal of Antimicrobial Chemotherapy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir plus lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial

The Journal of Antimicrobial Chemotherapy

相似文献

The Journal of Antimicrobial Chemotherapy

相关期刊

检索历史清除